Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
October 28, 2025
Endocrinology Today — October 28, 2025
October 28, 2025
Obesity Today — October 28, 2025
October 28, 2025
Lucid Diligence Brief: Guardant Health and Zephyr AI partnership
October 28, 2025
Obesity Video Recap — October 28, 2025
October 27, 2025
Hematology Today — October 27, 2025
October 27, 2025
Oncology Video Recap — October 27, 2025
October 27, 2025
Oncology Today — October 27, 2025
October 27, 2025
AI in Healthcare and Digital Health Today—October 27, 2025
October 27, 2025
Lucid Diligence Brief: Novartis to acquire Avidity Biosciences
October 26, 2025
Lucid Diligence Brief: ENA Respiratory Series B for Intranasal INNA-051
October 25, 2025
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies
October 24, 2025